Key Highlights

  • Bright Horizons Family Solutions is trading down 16.58% at $55.88 after a $290.0 million Goodwill Impairment and lower 2026 guidance.
  • Credit Acceptance is trading down 16.11% at $483.05 after a third-quarter net loss of $56.6 million.
  • Agios Pharmaceuticals is trading down 14.61% at $31.79 ahead of a Nov 1, 2026 FDA goal date.
  • Bandwidth is trading down 14.39% at $45.47 despite record third-quarter Revenue of $234 million.
  • Illumina is trading down 14.12% at $249.09 in the session after its scheduled third-quarter report.

Which Stocks Priced Above $30 Are Falling the Most Today?

Five stocks priced above $30 are trading sharply lower on Oct 30, 2026, each by more than 14%. Credit Acceptance (NASDAQ:CACC) is trading down 16.11% at $483.05, Illumina (NASDAQ:ILMN) is trading down 14.12% at $249.09, and Bandwidth (NASDAQ:BAND) is trading down 14.39% at $45.47. Bright Horizons Family Solutions (NYSE:BFAM) is trading down 16.58% at $55.88, and Agios Pharmaceuticals (NASDAQ:AGIO) is trading down 14.61% at $31.79.

All five percentages are measured against the previous close. Three of the five stories follow third-quarter Earnings reports released around Oct 29, 2026, while the Agios decline arrives ahead of a regulatory date and has no company-specific announcement identified. For Illumina and Bandwidth, the sources reviewed did not confirm the exact reason for the drop, and those articles say so. The sections below keep each company's cautions intact, including where figures predate today's slide.

Credit Acceptance: how did a lower collection forecast produce a loss?

Credit Acceptance reported a consolidated net loss of $56.6 million, or $5.43 per diluted share, for the quarter ended Sept 30, against Net Income of $108.2 million a year earlier. The swing was tied mainly to a methodology change that lowered forecasted collection rates on loans assigned from 2022 through 2026. The 2026 assignment-year forecast fell to 65.3% from 67.1% at the end of June.

The company provides auto financing programs through dealers to consumers with limited or impaired credit. Adjusted earnings per share, a non-GAAP measure, rose to $13.01 from $10.28, and Loan assignment dollar Volume climbed 51.0% to about $1.4 billion. Total Debt was about $6.72 billion against unrestricted cash of just $1.3 million, and during the quarter the company repurchased shares at an aggregate cost of $161.6 million.

Illumina: what is known about the drop after the third-quarter report date?

Illumina is trading down 14.12% at $249.09, which implies a prior close near $290. The company had scheduled its third-quarter results for Oct 29, but the specific figures and any guidance change behind today's reaction could not be confirmed, so no trigger is stated. Whether the report occurred as scheduled was also not confirmed.

Ahead of the report, market estimates called for earnings of $1.36 per share on revenue of $1.15 billion. The company supplies DNA sequencing and array technology, and launched its BioInsight Platform on Oct 14. Its July guidance called for full-year earnings of $5.30 to $5.40 per share, and the 52-week range was $94.00 to $309.35 as of Oct 26. At $271.04 on that date, the trailing price-to-earnings ratio was 50.47, a measure taken before today's decline.

Bandwidth: why are shares falling after a record revenue quarter?

Bandwidth is trading down 14.39% at $45.47 following its third-quarter report this week, and the sources reviewed did not state a specific reason for the drop. Revenue reached a record $234 million, up 22%, while adjusted EBITDA rose 43% to $35 million and free Cash Flow reached $33 million from $13 million.

Bandwidth runs a cloud communications platform and owns a U.S. carrier network. Full-year 2026 revenue guidance is $905 million to $910 million, but the company gave no fourth-quarter outlook. Management cited Demand tied to AI agents and a certification from Salesforce (NYSE:CRM) as its first international carrier for contact center in more than 25 countries. A market cap near $1.69 billion dates to early October and is stale. The company also expects double-digit cloud communications revenue growth in 2027.

Bright Horizons Family Solutions: how much did the impairment and guidance cut weigh?

Bright Horizons Family Solutions is trading down 16.58% at $55.88, a day after its third-quarter report on Oct 29. The company posted a net loss of $230.7 million, driven by a $290.0 million goodwill impairment mostly tied to Australia, plus higher tax and interest costs. GAAP loss per share was $4.76.

Beneath the charge, revenue rose 5% to $841.5 million and adjusted Earnings Per Share climbed 15% to $1.80. The company now expects 2026 adjusted earnings of $4.98 to $5.03 per share, below the $5.05 to $5.15 range given in July. It provides early education, back-up care and advisory services, and the prior close of roughly $67 is derived from the move.

Agios Pharmaceuticals: what sits behind the slide before the FDA date?

Agios Pharmaceuticals is trading down 14.61% at $31.79, and no company-specific announcement was identified. The FDA accepted its application for mitapivat in sickle cell disease under Priority Review, with a goal date of Nov 1, 2026, which is a Sunday.

The company develops rare disease therapies built around pyruvate kinase activators. It discontinued development of tebapivat earlier this year after mid-stage setbacks. The company has dosed the first patient in its Phase 3 REIGNITE confirmatory trial. Second-quarter mitapivat net revenue was $44.7 million, the net loss was $100.7 million, and cash and marketable securities were about $1 billion at the end of June.

Higher-Priced Decliners Compared: Average, Spread and Price Gap

The five stocks fell by an average of 15.16% (calculated). The spread between the largest decline, Bright Horizons Family Solutions at 16.58%, and the smallest, Illumina at 14.12%, is only 2.46 percentage points (calculated).

The price gap is much wider than the move gap. Credit Acceptance at $483.05 trades at about 15.2 times the price of Agios at $31.79 (calculated). Four of the five declines follow earnings or a scheduled regulatory event, though the link between results and the drop is confirmed only for Credit Acceptance and Bright Horizons, while Bandwidth and Illumina carry unconfirmed reasons. The percentage moves share one basis, the previous close.

What to Watch Next: The Nov 1 FDA Date and Fourth-Quarter Reports

The nearest dated event is the Nov 1, 2026 FDA goal date for mitapivat in sickle cell disease, and because it falls on a Sunday, any announcement may extend into the following week. Agios has not confirmed a third-quarter results date.

For Illumina, the Oct 29 results release and quarterly filing should clarify revenue and any guidance change. Bandwidth's next dated test is its fourth-quarter report, and Bright Horizons will be measured against its new 2026 guidance range in its fourth-quarter report. No dated release was identified for Credit Acceptance, though investors will follow the pace of loan assignments, Buybacks and funding.